Harvard University Expands Research Alliance with Northpond Labs to Accelerate Healthcare Innovation Translation
Key Insights
Harvard University has expanded its research alliance with Northpond Labs (search) to fund translational research across multiple schools including the Wyss Institute, Harvard Medical School, and engineering departments.
The collaboration builds on a successful 2020 partnership that led to the creation of EnPlusOne Biosciences (search), a startup developing enzymatic RNA synthesis platforms for next-generation RNA therapeutics (search).
Harvard Medical School will receive direct funding to de-risk promising therapeutic drug candidates and accelerate their progression toward clinical use.
Harvard University has significantly expanded its research alliance with Northpond Labs (search), the research and development-focused affiliate of Northpond Ventures (search), to accelerate the translation of breakthrough healthcare innovations from laboratory discoveries to clinical applications. The expanded collaboration will provide substantial funding for research across Harvard's Wyss Institute for Biologically Inspired Engineering (search), Harvard Medical School (HMS), John A. Paulson School of Engineering and Applied Sciences (SEAS), and Faculty of Arts and Sciences (FAS).
"Collaborations like this are essential for moving innovations from labs to real-world impact," said John H. Shaw, Senior Vice Provost for Research at Harvard University and Chair of the Board of Directors at the Wyss Institute. "Industry support strengthens our ability to translate academic research into solutions that spark innovation in the healthcare industry and benefit patients."
Building on Proven Success
The expanded alliance builds upon a successful partnership established in 2020 between Northpond Labs (search) and the Wyss Institute, which created the Lab for Bioengineering Research and Innovation. This initial collaboration demonstrated the effectiveness of academic-industry partnerships in advancing high-value technologies toward commercialization.
A notable success from the original alliance was support for the Controlled Enzymatic RNA Synthesis project, which led to the founding of EnPlusOne Biosciences (search). The startup is developing a scalable enzymatic RNA synthesis platform designed to enable next-generation RNA therapeutics (search). Additional supported projects from the initial collaboration remain in development or stealth mode.
University-Wide Research Acceleration
The new alliance represents a significant expansion in scope, involving laboratories across multiple Harvard schools. A substantial portion of the funding will be allocated to the Lab for Bioengineering Research and Innovation at the Wyss Institute, supporting scientists across Harvard's diverse research ecosystem.
"We are thrilled to expand our alliance with Northpond Labs (search) in fostering transformative, interdisciplinary technologies that can address some of healthcare's most pressing challenges and to help expand this collaboration across broader parts of the Harvard ecosystem," said Donald Ingber, MD, Ph.D., Founding Director of the Wyss Institute for Biologically Inspired Engineering (search) at Harvard University. "This university-wide support will leverage the Wyss model developed with Northpond to empower Harvard researchers to accelerate their discoveries from the lab to the clinic, ultimately benefiting patients worldwide."
Direct Clinical Translation Support
Harvard Medical School will receive dedicated funding to de-risk promising therapeutic drug candidates, advancing their progression toward clinical trials and supporting the school's research and service missions. This direct support aims to bridge the critical gap between laboratory discoveries and clinical applications.
"I am optimistic that this collaboration will help drive innovation in healthcare and move technologies closer to clinical use," said George Daley, Dean of Harvard Medical School. "Northpond Labs (search)' investment will enable us to support research that has the potential to improve medical outcomes for those who matter most: patients and their families."
Strategic Framework for Innovation
Harvard's Office of Technology Development established the framework for the expanded alliance, focusing on advancing research toward commercialization and streamlining the pathway from discovery to real-world impact. This structured approach aims to create sustainable mechanisms for translating academic research into healthcare solutions.
"Our expanded alliance with Harvard reflects a long-term commitment to building the infrastructure that turns foundational science into industry-defining innovation," said Mike Rubin, M.D., Ph.D., C.F.A., at Northpond Labs (search). "By partnering across the Wyss Institute, Harvard Medical School, SEAS, and FAS, we are helping to support a research ecosystem capable of delivering the transformative solutions of the coming years."
The collaboration represents a model for academic-industry partnerships that prioritize both scientific rigor and commercial viability, potentially serving as a blueprint for similar initiatives aimed at accelerating healthcare innovation translation.